A5 Laboratories (PINK:AFLB)

On June 18, 2010 we entered into a CRO asset acquisition agreement and an Interferon asset acquisition agreement (collectively, the “Agreements”) with Vida Nutra Pharma Inc., a company incorporated under the laws of Canada (“Vida”) and on July 5, 2010 we closed the transactions contemplated by the Agreements. Pursuant to the terms of the Agreements we issued options to acquire an aggregate of 1,000,000 shares of our common stock at $0.001 per share for a period of 60 months to Vida in exchange for the assets contemplated by the Agreements.

Going forward, we have abandoned our former business and will focus on provision of contract research and laboratory services (“CRO”) and the development of our interferon production technology.

Last updated July 25, 2010